The combination of metformin and pemetrexed exhibited an antiproliferative effect by affecting the cell cycle in non-small-cell lung cancer via downregulation of CCNA2 and CCND1, and the upregulation of CDKN1B (Wang et al., 2021b). This evidence concerns the gene CDKN1B and non-small cell lung carcinoma.